January 12, 2018 10:13 AM EST

HHS pick Azar draws the line on drug price negotiations at Medicare; AstraZeneca inks oncology research deal at JPM

Brittany Meiling

→ President Donald Trump’s pick to head HHS seems to have only a limited appetite for negotiating drug prices for Medicare. Alex Azar told a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

HHS pick Azar draws the line on drug price negotiations at Medicare; AstraZeneca inks oncology research deal at JPM

Brittany Meiling

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

HHS pick Azar draws the line on drug price ne­go­ti­a­tions at Medicare; As­traZeneca inks on­col­o­gy re­search deal at JPM

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

HHS pick Azar draws the line on drug price negotiations at Medicare; AstraZeneca inks oncology research deal at JPM